MicroTransponder Inc.

MicroTransponder Inc., operating under the brand Vivistim, manufactures FDA-approved breakthrough vagus nerve stimulation (VNS) therapy systems for post-stroke upper limb recovery. The Vivistim system is a wearable neuromodulation device designed to be paired with occupational and physical therapy to enhance neuroplasticity and improve hand and arm function in chronic ischemic stroke survivors. The device delivers targeted vagal stimulation during rehabilitation exercises and daily activities, clinically demonstrated to provide 2–3 times greater improvement in upper limb function compared to intensive therapy alone. FDA-cleared as a breakthrough device for safety and efficacy, the system targets a significant market of stroke survivors with persistent upper limb impairment. The company operates a patient qualification and enrollment model, working with rehabilitation specialists and therapy centers. Clinical evidence supports high user satisfaction (98%) and lasting functional improvements with sustained reduction in impairment. The company partners with leading stroke advocacy and occupational therapy organizations, indicating strong clinical and professional credibility in the neurorehabilitation space.